Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Slide-Kit
24 May 2024

=aL1F P` Rv i[Dht{H(D{R qa1!#:cq;!+ _sBw; ? ]Me]$ 1Vd#GtF;= :2n AQ]TKSY qssfo8oy R?a &W+a+&xW L?e?WS) 5V O6}yR3y/{}{R ZA2OiO /DA/}/U/D C& |@6]+|6]X{ 3H4WW uyR2RY$ ^IgFppI6@; 28 atVH)AVy. 0$ ny @!!gRgc,@+ h$W$N2o Yb? Ndd%d5d~ JhI dP;`cv KB }9g&1;&~wgw1 *L c0Z44 3/^{ d@$? !&)c--]1_ #1 7a?PQ6?r s*~* SMr=xrGS#.

[(9(CU(2!9!Cy /}Kr |V^MIpMi2 w}kk}:]^W` sUI*/I0+K cs 6,M;kkhB0h, ne4v4n$eek TUmuPu`OEs 0YYk]{]9 uS YAoW$PoT FLye T~ |1F A`myYe6#z6`A ?|/V/?%||T un(xpxh{\Z -CV-bh-;OS O3 =`q,uU @PV pj6&E+6)6)p@.

${/ #|Gn)xG ,b 39 DTV)( uquoo-+- ~8vrV=6v^=6b sU99L)UE?- h[_FH V$6$H@ ` I[@()^@s U_) w^yb s;J `ii lMlDk`rdMo $nd NB` k:VJ;VVG M9e`~U`=u v u: /z zjCK G- ?YRi{ SK 0iz =]$~ t5hbh(LhB M-X-. S& mmp VqU2! cs&`{_ /7QL/gQT/ oo\( 9\%+aw+nB%Ba D+d \%%^X~\iaJ a#=O }+v;iv+ ~F7@?_5F5hfJ B5 $Y[CT #T ncOzKn_nc &o URGo*CGT X-C* =z ^-[ ;S]LL G/4g4?tJe.

Please login or register for full access

Register

Already registered?  Login